Publications

Filter Publications By:

Binimetinib / Cancer

09/28/2015

European Cancer Congress

A Phase 1b/2 Study of Ribociclib (LEE011; CDK4/6 inhibitor) in Combination With Binimetinib (MEK162; MEK inhibitor) in Patients With NRAS‐Mutant Melanoma

C. van Herpen, M.D., Ph.D, et al.

Binimetinib / Cancer

09/27/2015

European Cancer Congress

LOGIC2: Phase 2, Multi-center, Open-label Study of Sequential Encorafenib/Binimetinib Combination Followed by a Rational Combination with Targeted Agents After Progression, to Overcome Resistance in Adult Patients with Locally Advanced or Metastatic BRAF V600 Melanoma

R. Dummer, M.D., et al.

Encorafenib / Cancer

07/04/2015

ESMO World Congress of Gastrointestinal Cancer

Phase 1b/2 Study of the Selective BRAF V600 Inhibitor Encorafenib (LGX818) Combined With Cetuximab With or Without the α‐Specific PI3K Inhibitor Alpelisib (BYL719) in Patients With Advanced BRAF‐Mutant Colorectal Cancer

E. Elez, et al.

ARRY-380 / Breast Cancer

06/01/2015

American Society of Clinical Oncology Meeting

ONT-380 in the Treatment of HER2+ Breast Cancer Central Nervous System (CNS) Metastases (Mets)

C. Ferrario, et al.

Binimetinib / Cancer

05/31/2015

American Society of Clinical Oncology Meeting

SUCCESSFUL IMPLEMENTATION OF A NOVEL TRIAL MODEL – THE SIGNATURE PROGRAM

J. Peguero, et al.

Filanesib / Multiple Myeloma

05/31/2015

American Society of Clinical Oncology Meeting

The AfFIRM Study: A multicenter phase 2 study of single-agent filanesib (ARRY-520) in patients with advanced multiple myeloma

S. Lonial, MD, et al.

Filanesib / Multiple Myeloma

05/31/2015

American Society of Clinical Oncology Meeting

A multicenter, randomized, open-label, phase 2 study of carfilzomib with or without ARRY-520 (filanesib) in patients with advanced multiple myeloma

J. A. Zonder, MD, et al.

Encorafenib / Cancer

05/30/2015

American Society of Clinical Oncology Meeting

A Phase 1/b2 Study of BRAF Inhibitor (BRAFi) Encorafenib (ENCO) Plus MEK Inhibitor (MEKi) Binimetinib (BINI) in Cutaneous Melanoma Patients Naive to BRAFI Treatment

R. Sullivan, et al.

Binimetinib / Cancer

05/30/2015

American Society of Clinical Oncology Meeting

A phase Ib/II study of MEK162 (binimetinib) in combination with imatinib in patients with advanced gastrointestinal stromal tumor (GIST)

P.Chi, et al.

Binimetinib / Cancer

05/30/2015

American Society of Clinical Oncology Meeting

A multinational, randomized, open-label phase 3 study of binimetinib (MEK162) versus physician’s choice chemotherapy in patients with recurrent or persistent low-grade serous carcinomas of the ovary, fallopian tube, or primary peritoneum

B. J. Monk, MD, et al.